For the quarter ending 2026-03-31, CNSP has $4,653,192 in assets. $4,582,487 in debts. $2,950,877 in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 2,950,877 | 7,201,014 | 9,864,087 | 12,129,873 |
| Deferred offering costs | 27,248 | 45,486 | 43,700 | 14,173 |
| Subscription receivable | - | 0 | 0 | 0 |
| Prepaid expenses and other current assets | 1,100,214 | 856,301 | 1,483,948 | 1,993,774 |
| Total current assets | 4,078,339 | 8,102,801 | 11,391,735 | 14,137,820 |
| Prepaid expenses, net of current portion | 552,839 | 502,962 | 474,416 | 366,251 |
| Property and equipment, net | 22,014 | 17,703 | 3,107 | 3,804 |
| Total noncurrent assets | 574,853 | 520,665 | 477,523 | 370,055 |
| Total assets | 4,653,192 | 8,623,466 | 11,869,258 | 14,507,875 |
| Accounts payable and accrued expenses | 4,350,134 | 3,772,339 | 1,928,324 | 1,261,123 |
| Notes payable | 232,353 | 328,571 | 30,793 | 121,767 |
| Total current liabilities | 4,582,487 | 4,100,910 | 1,959,117 | 1,382,890 |
| Total liabilities | 4,582,487 | 4,100,910 | 1,959,117 | 1,382,890 |
| Common stock, 0.001 par value, 300,000,000 shares authorized and 811,449 and 632,516 shares issued and outstanding, respectively | 811 | 633 | 574 | 504 |
| Additional paid-in capital | 105,282,208 | 104,797,191 | 104,229,033 | 104,225,466 |
| Accumulated deficit | -105,212,314 | -100,275,268 | -94,319,466 | -91,100,985 |
| Total stockholders' equity | 70,705 | 4,522,556 | 9,910,141 | 13,124,985 |
| Total liabilities and stockholders' equity | 4,653,192 | 8,623,466 | 11,869,258 | 14,507,875 |
CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc. (CNSP)